Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges
Tissue fibrosis may occur for unknown causes or be the consequence of many pathological conditions including chronic inflammatory or infectious diseases, autoimmune disorders, graft rejection, or malignancy. On the other hand, malignant tumors have been identified in fibrotic tissues decades ago, an...
Format: | eBook |
---|---|
Language: | English |
Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2019
|
Subjects: | |
Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
LEADER | 05385namaa2201405uu 4500 | ||
---|---|---|---|
001 | doab51774 | ||
003 | oapen | ||
005 | 20210211 | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 210211s2019 xx |||||o ||| 0|eng d | ||
020 | |a 9783039217069 | ||
020 | |a 9783039217076 | ||
020 | |a books978-3-03921-707-6 | ||
024 | 7 | |a 10.3390/books978-3-03921-707-6 |2 doi | |
040 | |a oapen |c oapen | ||
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
720 | 1 | |a Gabazza, Esteban C. |4 aut | |
245 | 0 | 0 | |a Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges |
260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2019 | ||
300 | |a 1 online resource (348 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
520 | |a Tissue fibrosis may occur for unknown causes or be the consequence of many pathological conditions including chronic inflammatory or infectious diseases, autoimmune disorders, graft rejection, or malignancy. On the other hand, malignant tumors have been identified in fibrotic tissues decades ago, and now accumulating evidence suggests that fibrotic lesions enhance the risk of cancer in several organs such as liver, lungs, and breast. Disruption of an organ parenchymal cells and of its normal structural scaffold during tissue fibrogenesis appears to induce loss of cell polarity, promoting uncontrolled cell proliferation that may eventually lead to cancer development. Many cellular and molecular abnormalities including aberrant expression of microRNAs, genetic and epigenetic alterations, evasion or delayed apoptosis, unregulated intracellular signal pathways, and dysregulation or defective intercellular communications have been proposed to explain this link between fibrogenesis and carcinogenesis. However, the precise mechanisms of this fibrosis-to-cancer transition remain unclear. This book presents a collection of reviews and original articles summarizing recent advances in understanding the molecular mechanisms of cancer development in fibrotic organs. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |u https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
653 | |a acute lung injury | ||
653 | |a anaplastic lymphoma kinase | ||
653 | |a angiogenesis | ||
653 | |a antitumor efficacy | ||
653 | |a apoptosis | ||
653 | |a bleomycin | ||
653 | |a breast cancer | ||
653 | |a butylidenephthalide | ||
653 | |a cancer | ||
653 | |a cancer-associated fibroblasts | ||
653 | |a cancer-associated fibroblasts (CAFs) | ||
653 | |a carcinogenesis | ||
653 | |a cirrhosis | ||
653 | |a clinical symptoms | ||
653 | |a common pathways | ||
653 | |a crizotinib | ||
653 | |a cystic formation | ||
653 | |a cytokine | ||
653 | |a cytokines | ||
653 | |a DHA | ||
653 | |a diagnosis | ||
653 | |a EMT | ||
653 | |a Erk1/2 | ||
653 | |a extracellular matrix | ||
653 | |a fibrosis | ||
653 | |a genetic instability | ||
653 | |a GPR120 | ||
653 | |a GPR40 | ||
653 | |a growth factor | ||
653 | |a HBV | ||
653 | |a HCV | ||
653 | |a hepatic stellate cells | ||
653 | |a hepatic stellate cells (HSCs) | ||
653 | |a hepatocellular carcinoma | ||
653 | |a hepatocellular carcinoma (HCC) | ||
653 | |a hepatocytes | ||
653 | |a heterogeneity | ||
653 | |a Hippo pathway | ||
653 | |a idiopathic pulmonary fibrosis | ||
653 | |a idiopathic pulmonary fibrosis (IPF) | ||
653 | |a immunohistochemistry | ||
653 | |a inflammation | ||
653 | |a interstitial fluid pressure | ||
653 | |a leiomyoma | ||
653 | |a leiomyosarcoma | ||
653 | |a lipopolysaccharide | ||
653 | |a lncRNA | ||
653 | |a lung cancer | ||
653 | |a lung cancer (LC) | ||
653 | |a marker | ||
653 | |a mechanotransduction | ||
653 | |a metabolic reprogramming | ||
653 | |a metastasis | ||
653 | |a miRNA | ||
653 | |a myometrium | ||
653 | |a n/a | ||
653 | |a nanoparticles | ||
653 | |a non-alcoholic steatohepatitis | ||
653 | |a non-small cell lung cancer (NSCLC) | ||
653 | |a omega-3 fatty acid | ||
653 | |a pathogenesis | ||
653 | |a pathology | ||
653 | |a pathophysiology | ||
653 | |a protein S | ||
653 | |a pulmonary fibrosis | ||
653 | |a reactive oxygen species | ||
653 | |a regeneration | ||
653 | |a renal injury | ||
653 | |a signal pathway | ||
653 | |a SMAD | ||
653 | |a smooth muscle tumor of uncertain malignant potential | ||
653 | |a SOX2 | ||
653 | |a SREBP-1 | ||
653 | |a targeted therapy | ||
653 | |a TAZ | ||
653 | |a TGF-? | ||
653 | |a therapy | ||
653 | |a transforming growth factor-? | ||
653 | |a tumor | ||
653 | |a tumor microenvironment | ||
653 | |a tumor necrosis factor ? | ||
653 | |a tumor stiffness | ||
653 | |a type I collagen | ||
653 | |a uterine fibroid | ||
653 | |a Wnt | ||
653 | |a YAP | ||
793 | 0 | |a DOAB Library. | |
856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/51774 |7 0 |z Open Access: DOAB: description of the publication |
856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/1794 |7 0 |z Open Access: DOAB, download the publication |